Immunogenicity of influenza vaccines administered to pregnant women in randomized clinical trials in Mali and South Africa. Issue 41 (22nd September 2020)

• Record Type: Journal Article
• Authors: Amin, Avnika B.; Nunes, Marta C.; Tapia, Milagritos D.; Madhi, Shabir A.; Cutland, Clare L.; Wairagkar, Niteen; Omer, Saad B.
• Is Part Of: Vaccine. Volume 38:Issue 41(2020)
• Page Start: 6478
• Page End: 6483
• Publication Date: 2020-09-22
• Subjects: Influenza -- Influenza vaccine -- Maternal vaccination -- Immunogenicity -- Transplacental antibody transfer; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.07.020
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Background: A key consideration for expanding recommendations for influenza vaccination is a robust assessment of immunogenicity and efficiency of transplacental antibody transfer after maternal vaccination. Methods: We pooled data from two trials of maternal influenza vaccination to analyze vaccine immunogenicity with more power than either trial had alone. We compared hemagglutination-inhibition (HAI) titers and titer factor change for women and their infants between trial arms using t-tests; maternal and infant putative seroprotective titers (HAI ≥ 1:40) within each trial arm and maternal seroconversion between trial arms using exact tests; and transplacental antibody transfer between trial arms using t-tests. We used marginal linear models and generalized estimating equations to examine the impact of time between maternal vaccination and delivery on transplacental antibody transfer, infant titers, and infant seroprotection. Results: For all vaccine components (A/H1N1, A/H3N2, and Type B), >80% of vaccinated women had seroprotective titers, >60% of them seroconverted, and >50% of their infants were born with seroprotective titers. These immunogenicity outcomes occurred more often in vaccine recipients and their infants than in controls. No difference in efficiency of transplacental antibody transfer was observed between vaccine recipients and controls. Conclusions: Our results provide robust support for further expansion of maternal influenza vaccination recommendations. Clinical Trials Registration: NCT01430689 and NCT01306669.